Johnson & Johnson Stock Price Analysis 2025: Recovery and Key Levels at $134-$148

Johnson & Johnson (NYSE: JNJ), a leading healthcare conglomerate and Dow Jones Industrial Average component, has demonstrated resilience with its stock rebounding after recent volatility. The company reported stronger-than-expected earnings before the market opened, marking its 28th consecutive quarter surpassing earnings per share (EPS) estimates, reinforcing investor confidence.

Following a sharp decline from its December 2023 peak of $148.99 to a Christmas Eve low of $121.00, JNJ shares have staged a recovery, closing recently above pivotal monthly and quarterly price levels at approximately $134.79 and $135.38 respectively. Year-to-date, the stock has gained 2.9%, and it is up nearly 10% from its late-December low.

With a current price-to-earnings (P/E) ratio of 15.10 and a dividend yield near 2.89%, Johnson & Johnson remains attractively valued. The company is also nearing a resolution regarding its involvement in the U.S. opioid crisis, with settlement figures estimated around $4 billion, which has positively influenced market sentiment.

The daily chart highlights a significant bottom formation at $121.00 in late 2023, with key resistance levels identified at $134.79 (monthly pivot) and $135.38 (quarterly pivot). Proprietary analytics indicate an annual risk threshold near $148.73 and a semiannual risk level around $155.92, suggesting potential upside targets if momentum continues.

On the weekly timeframe, JNJ is trading above its five-week modified moving average of $132.18 and comfortably above the 200-week simple moving average at $127.19, a critical long-term support level. Technical indicators, including the 12x3x3 weekly slow stochastic, point toward strengthening momentum, with readings climbing from 33.78 to an anticipated 47.96 this week.

Trading Strategy: Investors are advised to consider purchasing Johnson & Johnson shares on pullbacks toward the 200-week SMA near $127.19 to capitalize on long-term support. Conversely, reducing exposure near the annual risk level of $148.73 may help lock in gains. Monitoring monthly and quarterly pivot points at $134.79 and $135.38 can guide tactical entry and exit decisions.

Analytical Approach: Value and risk levels are calculated using the last nine monthly, quarterly, semiannual, and annual closing prices, capturing a comprehensive view of price volatility over nearly a decade. These levels help investors identify optimal buying opportunities on weakness and prudent profit-taking points on strength. Pivots, defined as breached value or risk levels within their respective timeframes, tend to act as magnets, often retested before expiration.

Disclaimer: The author holds no positions in Johnson & Johnson and does not intend to initiate any trades within the next 72 hours.

Discover engaging topics and analytical content in Company News as of 22-10-2019. The article titled " Johnson & Johnson Stock Price Analysis 2025: Recovery and Key Levels at $134-$148 " provides new insights and practical guidance in the Company News field. Each topic is meticulously analyzed to deliver actionable information to readers.

The topic " Johnson & Johnson Stock Price Analysis 2025: Recovery and Key Levels at $134-$148 " helps you make smarter decisions within the Company News category. All topics on our website are unique and offer valuable content for our audience.